These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 35396889

  • 1. Plerixafor stem cell mobilization in Japanese children: A post-marketing study.
    Goto H, Kanamori R, Nishina S, Seto T.
    Pediatr Int; 2022 Jan; 64(1):e15106. PubMed ID: 35396889
    [Abstract] [Full Text] [Related]

  • 2. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D, Ali S, van Hennik PB, Straus S, Josephson F, Thole G, Glerum PJ, Herberts C, Babae N, Herold R, Papadouli I, Pignatti F.
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [Abstract] [Full Text] [Related]

  • 3. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C, Dehghani M, Hopman W, Bhella S.
    J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
    Ri M, Matsue K, Sunami K, Shimazaki C, Hayashi A, Sunaga Y, Sasaki T, Suzuki K.
    Int J Hematol; 2017 Oct; 106(4):562-572. PubMed ID: 28527129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
    Malinowska I, Romiszewski M, Smalisz K, Stelmaszczyk-Emmel A, Nasilowska-Adamska B, Krol M, Urbanowska E, Brozyna A, Baginska-Dembowska B.
    Transfus Apher Sci; 2021 Jun; 60(3):103077. PubMed ID: 33583716
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
    Chen KY, Bucci TG, Shaw JR, Alexander MD, Grgic T, Riches M, Ptachcinski JR.
    Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of a reduced dose of plerixafor in combination with granulocyte colony-stimulating factor in healthy haploidentical stem cell donors.
    Kurnikova E, Trakhtman P, Balashov D, Garloeva J, Kumukova I, Khismatullina R, Pershin D, Shelikhova L, Novichkova G, Maschan A.
    Vox Sang; 2022 Jun; 117(6):853-861. PubMed ID: 35332550
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ, Milone G, Pareja MO, Shaheen D, Willemsen A, Whitaker N, Chabannon C.
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
    [Abstract] [Full Text] [Related]

  • 14. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T, Lunzer V, Greil R, Namberger K, Hartmann TN.
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [Abstract] [Full Text] [Related]

  • 15. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M, Silva M.
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [Abstract] [Full Text] [Related]

  • 16. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
    DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigators.
    J Clin Oncol; 2009 Oct 01; 27(28):4767-73. PubMed ID: 19720922
    [Abstract] [Full Text] [Related]

  • 17. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct 01; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 18. Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant.
    Fergadis E, Assi A, Kranidioti E, Kosma A, Karakosta M, Miltiadous C, Dimitriadis GK, Grivas A, Athanasopoulos A, Lianos E, Kosmas C.
    Clin Lymphoma Myeloma Leuk; 2020 Feb 01; 20(2):e50-e57. PubMed ID: 31884151
    [Abstract] [Full Text] [Related]

  • 19. [A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].
    Chen J, Yuan LL, Zhang X, Qiao JL, Yin QX, Zhang YM, Yang XL, Cao XY.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb 01; 30(1):286-291. PubMed ID: 35123641
    [Abstract] [Full Text] [Related]

  • 20. MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
    Iida S, Ishida T, Miyamoto T, Teramukai S, Shirai H, Kanamori R, Tajima Y, Crawford B, Yi J, Teshima T.
    Int J Hematol; 2022 Sep 01; 116(3):411-422. PubMed ID: 35551631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.